Prion Disorders


Prion diseases are neurodegenerative conditions that, in contrast to Alzheimer, Parkinson and other neurodegenerative diseases, are transmissible from one individual to another. The infectious agent causing prion diseases has been proposed to consist exclusively of a protein. The exact mechanism by which the agent replicates is still unclear.

Keywords: prion protein; PrPSc; PrPC; transmissible spongiform encephalopathies; scrapie; protein‐only hypothesis; neuroinvasion; amyloid plaques; microglia; transgenic mice; knockout mice

Figure 1.

Models for the conformational conversion of PrPC into PrPSc. (a) The ‘refolding’ or template assistance model postulates an interaction between exogenously introduced PrPSc and endogenous PrPC, which is induced to transform itself into further PrPSc. A high‐energy barrier may prevent spontaneous conversion of PrPC into PrPSc. (b) The ‘seeding’ or nucleation‐polymerization model proposes that PrPC and PrPSc are in a reversible thermodynamic equilibrium. Only of several monomeric PrPSc molecules are mounted into a highly ordered seed, can further monomeric PrPSc and eventually aggregates of amyloid be recruited. Within such a crystal‐like seed, PrPSc becomes stabilized. Fragmentation of PrPSc aggregates increases the number of nuclei, which can recruit further PrPSc and thus result in apparent replication of the agent.

Figure 2.

Posttranslational processing of PrPC. The coding region of the human PrP gene displaying the N‐ and C‐terminal signal sequences. Upon reaching its destination on the cell surface, an N‐terminal secretory signal peptide of 22 amino acids is cleaved from the 254 amino acid PrPC precursor protein. Twenty‐three C‐terminal residues are also processed during addition of the (GPI) anchor to a serine residue at position 231. Upon completion of these modifications, mature PrPC contains 209 amino acids. PrPSc is a modified form of PrPC. PrPC and PrPSc have an identical amino acid sequence and share the same posttranslational modifications, but differ in their secondary and (presumably) tertiary structures. The physiological isoform PrPC is protease‐sensitive, while the pathological isoform PrPSc is partially protease‐resistant, displaying a protease‐resistant core of PrPSc, designated PrP27–30.

Figure 3.

Patterns of PrP glycosylation. Representation of the three glycosylated PrPSc moieties (non‐, mono‐ and diglycosylated PrPSc) in immunoblots of brain extracts after digest with proteinase K. Different inocula result in specific mobilities of the three PrP bands as well as different predominance of certain bands (middle panel). These characteristic patterns can be retained, or changed to other predictable patterns after passage in wild‐type mice (upper panel) or humanized mice (PrP‐deficient mice bearing a human PrP transgene, lower panel). On the basis of the fragment size and the relative abundance of individual bands, three distinct patterns (PrPSc types 1–3) were defined for sporadic and iatrogenic CJD cases. By contrast, all cases of nvCJD displayed a novel pattern, designated a type‐4 pattern.

Figure 4.

Characteristic neuropathologic features of transmissible spongiform encephalopathies. Gray matter of the brain of a CJD patient stained with (H & E) displaying the characteristic spongiform, vacuole‐like morphology (left). Activation and proliferation of reactive, swollen astrocytes is visualized by staining with antibodies against (GFAP, brown color, middle). Immunohistochemical staining using anti‐PrP antibodies representing prion protein deposits (brown color, right).



Aguzzi A (1996) Between cows and monkeys. Nature 381: 734.

Aguzzi A and Weissmann C (1996) Spongiform encephalopathies: a suspicious signature. Nature 383: 666–667.

Basler K, et al. (1986) Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell 46: 417–428.

Belay ED (1999) Transmissible spongiform encephalopathies in humans. Annual Review of Microbiolgy 53: 283–314.

Bessen RA and Marsh RF (1994) Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. Journal of Virology 68: 7859–7868.

Bessen RA, Raymond GJ and Caughey B (1997) In situ formation of protease‐resistant prion protein in transmissible spongiform encephalopathy‐infected brain slices. Journal of Biological Chemistry 272: 15227–15231.

Bessen RA, et al. (1995) Non‐genetic propagation of strain‐specific properties of scrapie prion protein. Nature 375: 698–700.

Brown P (1998) Transmission of spongiform encephalopathy through biological products. Development of Specifications for Biotechnology Pharmaceutical Products 93: 73–78.

Bruce ME, Fraser H, McBride PA, Scott JR and Dickinson AG (1992) In: Prusiner SB, Collinge J, Powell J and Anderton B (eds.) Prion Diseases of Humans and Animals, pp. 497–508. New York, NY/London, UK: Ellis Horwood.

Bruce ME, et al. (1997) Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389: 498–501.

Büeler HR, et al. (1992) Normal development and behavior of mice lacking the neuronal cell‐surface PrP protein. Nature 356: 577–582.

Büeler HR, et al. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73: 1339–1347.

Carlson GA, et al. (1986) Linkage of prion protein and scrapie incubation time genes. Cell 46: 503–511.

Caughey WS, Raymond LD, Horiuchi M and Caughey B (1998) Inhibition of protease‐resistant prion protein formation by porphyrins and phthalocyanines. Proceedings of the National Academy of Sciences of the United States of America 95: 12117–12122.

Chesebro B, et al. (1985) Identification of scrapie prion protein‐specific mRNA in scrapie‐infected and uninfected brain. Nature 315: 331–333.

Collinge J, Sidle KC, Meads J, Ironside J and Hill AF (1996) Molecular analysis of prion strain variation and the etiology of ‘new variant’ CJD. Nature 383: 685–690.

DeArmond SJ, et al. (1997) Selective neuronal targeting in prion disease. Neuron 19: 1337–1348.

DeArmond SJ, et al. (1999) PrPc glycoform heterogeneity as a function of brain region: implications for selective targeting of neurons by prion strains. Journal of Neuropathology and Experiment Neurology 58: 1000–1009.

Dickinson AG, Meikle VM and Fraser H (1968) Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. Journal of Comparative Pathology 78: 293–299.

Farquhar C, Dickinson A and Bruce M (1999) Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. The Lancet 353: 117.

Gajdusek DC, Gibbs CJ and Alpers M (1966) Experimental transmission of a Kuru‐like syndrome to chimpanzees. Nature 209: 794–796.

Gibbs Jr CJ, et al. (1968) Creutzfeldt–Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161: 388–389.

Giese A, et al. (1998) Role of microglia in neuronal cell death in prion disease. Brain Pathology 8: 449–457.

Griffith JS (1967) Self‐replication and scrapie. Nature 215: 1043–1044.

Hill AF, et al. (1997) The same prion strain causes vCJD and BSE. Nature 389: 448–450.

Hope J (1999) Spongiform encephalopathies. Breech‐birth prions. Nature 402: 737–739.

Hsiao K, et al. (1991) Mutation of the prion protein in Libyan Jews with Creutzfeldt–Jakob disease. New England Journal of Medicine 324: 1091–1097.

Hunter N, Hope J, McConnell I and Dickinson AG (1987) Linkage of the scrapie‐associated fibril protein (PrP) gene and Sinc using congenic mice and restriction fragment length polymorphism analysis. Journal of General Virology 68: 2711–2716.

Jakob A (1921) Über eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswertem anatomischem Befunde. (Spastische Pseudosklerose‐Encephalomyelopathie mit disseminierten Degenerationsherden). Zeitschrift der gesamten Neurologie und Psychiatrie 64: 147–228.

Jarrett JT and Lansbury Jr PT (1993) Seeding ‘one‐dimensional crystallization’ of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055–1058.

Kahana E, Alter M, Braham J and Sofer D (1974) Creutzfeldt–Jakob disease: focus among Libyan Jews in Israel. Science 183: 90–91.

Kocisko DA, Lansbury PT and Caughey B (1996) Partial unfolding and refolding of scrapie‐associated prion protein – evidence for a critical 16‐kDa C‐terminal domain. Biochemistry 35: 13434–13442.

Kocisko DA, et al. (1995) Species specificity in the cell‐free conversion of prion protein to protease‐resistant forms: a model for the scrapie species barrier. Proceedings of the National Academy of Sciences of the United States of America 92: 3923–3927.

Lantos PL (1992) From slow virus to prion: a review of transmissible spongiform encephalopathies. Histopathology 20: 1–11.

Manson JC, et al. (1994) 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Molecular Neurobiology 8: 121–127.

Manson JC, et al. (1999) A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO Journal 18: 6855–6864.

Martins VR, et al. (1997) Complementary hydropathy identifies a cellular prion protein receptor. Nature Medicine 3: 1376–1382.

McGill IS and Wells GA (1993) Neuropathological findings in cattle with clinically suspect but histologically unconfirmed bovine spongiform encephalopathy (BSE). Journal of Comparative Pathology 108: 241–260.

Moore RC, et al. (1999) Ataxia in prion protein (PrP)‐deficient mice is associated with upregulation of the novel PrP‐like protein doppel. Journal of Molecular Biology 292: 797–817.

Nishida N, et al. (1999) A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Laboratory Investigation 79: 689–697.

Pan KM, et al. (1993) Conversion of alpha‐helices into beta‐sheets features in the formation of the scrapie prion proteins. Proceedings of the National Academy of Sciences of the United States of America 90: 10962–10966.

Pattison IH (1966) The relative susceptibility of sheep, goats and mice to two types of the goat scrapie agent. Research in Veterinary Science 7: 207–212.

Pattison IH and Millson GC (1961) Experimental transmission of scrapie to goats and sheep by the oral route. Journal of Comparative Pathology 71: 171–176.

Powell Jackson J, et al. (1985) Creutzfeldt–Jakob disease after administration of human growth hormone. Lancet 2: 244–246.

Priola SA, Raines A and Caughey WS (2000) Porphyrin and phthalocyanine antiscrapie compounds. Science 287: 1503–1506.

Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144.

Prusiner SB (1989) Scrapie prions. Annual Review of Microbioogy 43: 345–374.

Prusiner SB, et al. (1990) Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63: 673–686.

Rieger R, Edenhofer F, Lasmezas CI and Weiss S (1997) The human 37‐kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nature Medicine 3: 1383–1388.

Riesner D, et al. (1993) Prions and nucleic acids: search for ‘residual’ nucleic acids and screening for mutations in the PrP‐gene. Developments in Biological Standardization 80: 173–181.

Sailer A, Büeler H, Fischer M, Aguzzi A and Weissmann C (1994) No propagation of prions in mice devoid of PrP. Cell 77: 967–968.

Sakaguchi S, et al. (1995) Accumulation of proteinase K‐resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse‐adapted strain of the Creutzfeldt–Jakob disease agent. Journal of Virology 69: 7586–7592.

Sakaguchi S, et al. (1996) Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature 380: 528–531.

Scott M, et al. (1989) Transgenic mice expressing hamster prion protein produce species‐specific scrapie infectivity and amyloid plaques. Cell 59: 847–857.

Shmerling D, et al. (1998) Expression of amino‐terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93: 203–214.

Soto C, et al. (2000) Reversion of prion protein conformational changes by synthetic beta‐sheet breaker peptides. Lancet 355: 192–197.

Telling GC, et al. (1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83: 79–90.

Telling GC, et al. (1996) Interactions between wild‐type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes and Development 10: 1736–1750.

Weber T and Aguzzi A (1997) The spectrum of transmissible spongiform encephalopathies. Intervirology 40: 198–212.

Weissmann C and Aguzzi A (1997) Bovine spongiform encephalopathy and early onset variant Creutzfeldt–Jakob disease. Current Opinion in Neurobiology 7: 695–700.

Weissmann C and Aguzzi A (1999) Perspectives: neurobiology. PrP's double causes trouble. Science 286: 914–915.

Will R, et al. (1996) A new variant of Creutzfeldt–Jakob disease in the UK. Lancet 347: 921–925.

Yehiely F, et al. (1997) Identification of candidate proteins binding to prion protein. Neurobiology of Disease 3: 339–355.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Aguzzi, Adriano(Sep 2005) Prion Disorders. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1038/npg.els.0005170]